RU2011106331A - ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА - Google Patents
ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА Download PDFInfo
- Publication number
- RU2011106331A RU2011106331A RU2011106331/04A RU2011106331A RU2011106331A RU 2011106331 A RU2011106331 A RU 2011106331A RU 2011106331/04 A RU2011106331/04 A RU 2011106331/04A RU 2011106331 A RU2011106331 A RU 2011106331A RU 2011106331 A RU2011106331 A RU 2011106331A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- methyl
- day
- pharmaceutically acceptable
- body weight
- Prior art date
Links
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 238000000034 method Methods 0.000 claims abstract 17
- 241000124008 Mammalia Species 0.000 claims abstract 10
- 230000037396 body weight Effects 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 6
- HJWLJNBZVZDLAQ-UHFFFAOYSA-N n-methyl-1-[4-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide Chemical compound C1CC(CS(=O)(=O)NC)CCC1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-UHFFFAOYSA-N 0.000 claims abstract 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract 4
- 241001465754 Metazoa Species 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 208000010668 atopic eczema Diseases 0.000 claims abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract 2
- 208000014085 Chronic respiratory disease Diseases 0.000 claims abstract 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 208000003251 Pruritus Diseases 0.000 claims abstract 2
- 206010003246 arthritis Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 206010023332 keratitis Diseases 0.000 claims abstract 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 244000144972 livestock Species 0.000 claims abstract 2
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 230000009826 neoplastic cell growth Effects 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 3
- 239000011976 maleic acid Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение формулы I ! ! или его фармацевтически приемлемая соль, где R1 представляет собой С1-4 алкил, необязательно замещенный гидроксигруппой. ! 2. Соединение по п.1, в котором R1 представляет собой метил. ! 3. Соединение по п.1, в котором R1 представляет собой этил или циклобутил. ! 4. Соединение по п.1, которое представляет собой N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамид, или его фармацевтически приемлемой соли. ! 5. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель. ! 6. Способ лечения аллергических реакций, аллергического дерматита, атопического дерматита, экземы или зуда у млекопитающих, включающий введение нуждающемуся млекопитающему терапевтически эффективного количества соединения по п.1. ! 7. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,01 мг/кг веса тела/день до 100 мг/кг веса тела/день. ! 8. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,1 мг/кг веса тела/день до 10 мг/кг веса тела/день. ! 9. Способ по п.6, в котором млекопитающее включает животных-компаньонов. ! 10. Способ по п.9, в котором животными-компаньонами являются собаки. ! 11. Способ по п.6, в котором млекопитающее включает домашний скот. ! 12. Способ по п.6, в котором соединение по п.1 вводят перорально, парентерально или местно. ! 13. Способ лечения нейродегенеративных заболеваний, кератоконъюнктивита, хронических респираторных заболеваний, аутоиммунных заболеваний, воспалительного заболевания кишечника, неоплазии, артритных состояний, рака, лейкемии, волчанки и множественн
Claims (18)
1. Соединение формулы I
или его фармацевтически приемлемая соль, где R1 представляет собой С1-4 алкил, необязательно замещенный гидроксигруппой.
2. Соединение по п.1, в котором R1 представляет собой метил.
3. Соединение по п.1, в котором R1 представляет собой этил или циклобутил.
4. Соединение по п.1, которое представляет собой N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамид, или его фармацевтически приемлемой соли.
5. Фармацевтическая композиция, включающая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
6. Способ лечения аллергических реакций, аллергического дерматита, атопического дерматита, экземы или зуда у млекопитающих, включающий введение нуждающемуся млекопитающему терапевтически эффективного количества соединения по п.1.
7. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,01 мг/кг веса тела/день до 100 мг/кг веса тела/день.
8. Способ по п.6, в котором терапевтически эффективное количество составляет от 0,1 мг/кг веса тела/день до 10 мг/кг веса тела/день.
9. Способ по п.6, в котором млекопитающее включает животных-компаньонов.
10. Способ по п.9, в котором животными-компаньонами являются собаки.
11. Способ по п.6, в котором млекопитающее включает домашний скот.
12. Способ по п.6, в котором соединение по п.1 вводят перорально, парентерально или местно.
13. Способ лечения нейродегенеративных заболеваний, кератоконъюнктивита, хронических респираторных заболеваний, аутоиммунных заболеваний, воспалительного заболевания кишечника, неоплазии, артритных состояний, рака, лейкемии, волчанки и множественной миеломы у млекопитающего, включающий введение нуждающемуся в этом млекопитающему терапевтически эффективного количества соединения по п.1.
14. Кристаллическая Форма А соли N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой.
15. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,2, 12,6 и 15,7.
16. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,2, 12,6, 15,7, 18,5, 27 и 28,38.
17. Соединение по п.14, которое характеризуется порошковой рентгеновской дифрактограммой, имеющей по меньшей мере один характеристический пик, в области приблизительно следующих значений угла 2-тета: 6,178, 8,519, 12,601, 13,819, 15,478, 15,719, 16,32, 17,997, 18,539, 20,298, 20,659, 21,583, 22,642, 23,08, 24,86, 25,602, 26,582, 27,02, 27,721, 28,161, 28,38.
18. Способ получения Формы А соли N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой, включающий взаимодействие N-метил-1-{транс-4-[метил(7H-пирроло[2,3-d]пиримидин-4-ил)амино]циклогексил}метансульфонамида с малеиновой кислотой.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9037108P | 2008-08-20 | 2008-08-20 | |
| US61/090,371 | 2008-08-20 | ||
| PCT/IB2009/053514 WO2010020905A1 (en) | 2008-08-20 | 2009-08-10 | Pyrrolo[2,3-d]pyrimidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011106331A true RU2011106331A (ru) | 2012-08-27 |
| RU2493157C2 RU2493157C2 (ru) | 2013-09-20 |
Family
ID=41259411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011106331/04A RU2493157C2 (ru) | 2008-08-20 | 2009-08-10 | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8133899B2 (ru) |
| EP (1) | EP2384326B1 (ru) |
| JP (1) | JP4884570B2 (ru) |
| KR (1) | KR101335843B1 (ru) |
| CN (1) | CN102131812B (ru) |
| AR (2) | AR073073A1 (ru) |
| AU (1) | AU2009283844B2 (ru) |
| BR (1) | BRPI0917459B1 (ru) |
| CA (1) | CA2733359C (ru) |
| CL (1) | CL2011000353A1 (ru) |
| CO (1) | CO6331437A2 (ru) |
| DK (1) | DK2384326T3 (ru) |
| EC (1) | ECSP11010904A (ru) |
| ES (1) | ES2467109T3 (ru) |
| HR (1) | HRP20140395T1 (ru) |
| ME (1) | ME01269B (ru) |
| MX (1) | MX2011001904A (ru) |
| NZ (1) | NZ605292A (ru) |
| PL (1) | PL2384326T3 (ru) |
| PT (1) | PT2384326E (ru) |
| RS (1) | RS53382B (ru) |
| RU (1) | RU2493157C2 (ru) |
| SI (1) | SI2384326T1 (ru) |
| UY (1) | UY32059A (ru) |
| WO (1) | WO2010020905A1 (ru) |
| ZA (1) | ZA201101701B (ru) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| AU2010308028A1 (en) | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
| JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
| CA2782720A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2011104652A2 (en) * | 2010-02-24 | 2011-09-01 | Pfizer Inc. | Veterinary compositions |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| PE20141360A1 (es) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
| JP6129155B2 (ja) | 2011-04-12 | 2017-05-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 同種移植片拒絶反応を抑制する方法 |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN104619693B (zh) * | 2012-07-17 | 2019-08-13 | 葛兰素史克知识产权第二有限公司 | 作为选择性雄激素受体调节剂的吲哚腈类 |
| PT2874630T (pt) * | 2012-07-20 | 2019-01-31 | Zoetis Services Llc | Regime de dosagem para inibidores de janus quinase (jak) |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| WO2014118388A1 (en) | 2013-02-04 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| EA027879B1 (ru) * | 2013-02-22 | 2017-09-29 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| ES2962330T3 (es) | 2015-01-20 | 2024-03-18 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidor de jak |
| EP3290418B1 (en) | 2015-04-29 | 2019-05-15 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase (jak) inhibitors |
| DK3305788T3 (da) | 2015-05-29 | 2020-09-28 | Wuxi Fortune Pharmaceutical Co Ltd | Janus-kinase-hæmmer |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| WO2017134212A1 (en) * | 2016-02-05 | 2017-08-10 | Siegfried Ag | Process for the preparation of trans-4-amino-1-cyclohexanecarboxilic acid and its derivatives |
| RU2699034C1 (ru) * | 2016-02-16 | 2019-09-03 | ЗОИТИС СЕРВИСЕЗ ЭлЭлСи | Способ получения соединений 7H-пирроло[2,3-d]пиримидина |
| CN107365312B (zh) * | 2016-05-13 | 2021-10-01 | 瑞博(杭州)医药科技有限公司 | 一种制备Oclacitinib的新方法 |
| AU2017376398B2 (en) | 2016-12-14 | 2021-07-15 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| BR112019024509A2 (pt) | 2017-05-23 | 2020-06-23 | Theravance Biopharma R&D Ip, Llc | Glicuronídeo de pró-fármacos dos inibidores da janus quinase |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| CA3093709C (en) | 2018-03-16 | 2024-03-26 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン３１モノクローナル抗体 |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| JP2022506682A (ja) * | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ，インコーポレーテッド | 化合物 |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| DK3915989T3 (da) * | 2019-01-30 | 2023-09-18 | Felicamed Biotechnology Co Ltd | Jak inhibitor and preparation method therefor |
| CN113438941A (zh) | 2019-02-20 | 2021-09-24 | 硕腾服务有限责任公司 | 可口制剂 |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗ｉｌ３１抗体 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021123092A1 (en) | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
| RS64823B1 (sr) | 2020-03-13 | 2023-12-29 | Astrazeneca Ab | Fuzionisana pirimidinska jedinjenja kao modulatori kcc2 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN112279854B (zh) * | 2020-08-25 | 2022-04-05 | 常州齐晖药业有限公司 | 一种7H-吡咯并[2,3-d]嘧啶化合物的制备方法 |
| JP7905331B2 (ja) | 2020-10-15 | 2026-08-14 | インターベット インターナショナル ベー． フェー． | イヌインターロイキン－３１受容体アルファに対するイヌ化抗体 |
| WO2022133420A1 (en) | 2020-12-18 | 2022-06-23 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
| CA3211221A1 (en) | 2021-02-22 | 2022-08-25 | Zoetis Services Llc | Horse il-31 induced pruritus model |
| US20240368249A1 (en) | 2021-08-20 | 2024-11-07 | Intervet Inc. | Fusion proteins for treating atopic dermatitis |
| AU2022409610A1 (en) | 2021-12-16 | 2024-05-30 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha 1 |
| WO2023118555A1 (en) | 2021-12-24 | 2023-06-29 | Intervet International B.V. | Use of aminopyrazole compounds |
| CN114605420B (zh) * | 2022-04-25 | 2024-07-12 | 江苏慧聚药业股份有限公司 | 马来酸奥拉替尼的合成方法 |
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037980A (en) * | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| GB915304A (en) | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives |
| US3670079A (en) * | 1970-10-06 | 1972-06-13 | Merck & Co Inc | Anabolic agents |
| US4997936A (en) * | 1977-10-19 | 1991-03-05 | Merck & Co., Inc. | 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids |
| US4456464A (en) * | 1982-05-19 | 1984-06-26 | Zoecon Corporation | Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control |
| US4526608A (en) * | 1982-07-14 | 1985-07-02 | Zoecon Corporation | Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use |
| US4590282A (en) * | 1984-09-24 | 1986-05-20 | Sandoz Ltd. | Pest control agents |
| US4933339A (en) * | 1985-08-21 | 1990-06-12 | Rohm And Haas Company | (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity |
| CA1328333C (en) * | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
| NO169490C (no) | 1988-03-24 | 1992-07-01 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater |
| US4879309A (en) * | 1988-09-27 | 1989-11-07 | Schering Corporation | Mercapto-acylamino acids as antihypertensives |
| JP2983254B2 (ja) * | 1989-06-14 | 1999-11-29 | 武田薬品工業株式会社 | ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体 |
| US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
| US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| CA2223081C (en) | 1995-06-07 | 2001-03-06 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| MX9800136A (es) | 1995-07-05 | 1998-03-29 | Du Pont | Pirimidinonas fungicidas. |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| HUP9801177A3 (en) | 1995-11-14 | 1998-11-30 | Pharmacia & Upjohn Spa | Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US6140317A (en) | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| WO1997032879A1 (de) | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| AR007855A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| IL129825A0 (en) | 1996-11-27 | 2000-02-29 | Pfizer | Fused bicyclic pyrimidine derivatives |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| WO1998043087A1 (en) * | 1997-03-24 | 1998-10-01 | Pharmacia & Upjohn Company | Method for identifying inhibitors of jak2/cytokine receptor binding |
| US6310063B1 (en) * | 1998-04-02 | 2001-10-30 | Neurogen Corporation | Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors |
| HUP0102793A3 (en) | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| AU3951899A (en) * | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法 |
| AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| NZ510588A (en) | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| AU7738000A (en) * | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| OA12118A (en) * | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| OA12292A (en) * | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| KR100600550B1 (ko) * | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| PY0228255A (es) * | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| WO2004047843A1 (en) * | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| US7253166B2 (en) * | 2003-04-22 | 2007-08-07 | Irm Llc | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells |
| WO2005020921A2 (en) * | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| RU2006120956A (ru) * | 2003-12-17 | 2008-01-27 | Пфайзер Продактс Инк. (Us) | Пирроло{2, 3-d}пиримидиновые соединения для лечения отторжения трансплантата |
| MXPA06007095A (es) * | 2003-12-22 | 2006-09-04 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de cinasa. |
| WO2005074603A2 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| CA2572331A1 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
-
2009
- 2009-08-10 RS RS20140332A patent/RS53382B/sr unknown
- 2009-08-10 DK DK09786882.2T patent/DK2384326T3/da active
- 2009-08-10 PL PL09786882T patent/PL2384326T3/pl unknown
- 2009-08-10 CN CN200980132519.2A patent/CN102131812B/zh active Active
- 2009-08-10 CA CA2733359A patent/CA2733359C/en active Active
- 2009-08-10 HR HRP20140395AT patent/HRP20140395T1/hr unknown
- 2009-08-10 RU RU2011106331/04A patent/RU2493157C2/ru not_active Application Discontinuation
- 2009-08-10 WO PCT/IB2009/053514 patent/WO2010020905A1/en not_active Ceased
- 2009-08-10 MX MX2011001904A patent/MX2011001904A/es active IP Right Grant
- 2009-08-10 SI SI200930918T patent/SI2384326T1/sl unknown
- 2009-08-10 JP JP2011523467A patent/JP4884570B2/ja active Active
- 2009-08-10 ES ES09786882.2T patent/ES2467109T3/es active Active
- 2009-08-10 NZ NZ605292A patent/NZ605292A/en unknown
- 2009-08-10 ME MEP-2011-22A patent/ME01269B/me unknown
- 2009-08-10 KR KR1020117003834A patent/KR101335843B1/ko active Active
- 2009-08-10 AU AU2009283844A patent/AU2009283844B2/en active Active
- 2009-08-10 BR BRPI0917459-1A patent/BRPI0917459B1/pt active IP Right Grant
- 2009-08-10 EP EP09786882.2A patent/EP2384326B1/en active Active
- 2009-08-10 PT PT97868822T patent/PT2384326E/pt unknown
- 2009-08-17 US US12/542,451 patent/US8133899B2/en active Active
- 2009-08-18 AR ARP090103164A patent/AR073073A1/es not_active Application Discontinuation
- 2009-08-19 UY UY0001032059A patent/UY32059A/es active IP Right Grant
-
2011
- 2011-02-18 CL CL2011000353A patent/CL2011000353A1/es unknown
- 2011-02-18 CO CO11019992A patent/CO6331437A2/es active IP Right Grant
- 2011-03-04 ZA ZA2011/01701A patent/ZA201101701B/en unknown
- 2011-03-21 EC EC2011010904A patent/ECSP11010904A/es unknown
-
2012
- 2012-01-30 US US13/360,963 patent/US8987283B2/en active Active
-
2015
- 2015-02-11 US US14/619,195 patent/US9161939B2/en active Active
- 2015-09-15 US US14/854,632 patent/US9271981B2/en active Active
-
2016
- 2016-10-04 AR ARP160103034A patent/AR106252A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2583086T3 (es) | Pirazolopiridinas sustituidas con fluoroalquilo y su uso | |
| NZ605292A (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| ES2908150T3 (es) | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 | |
| EP4363412A1 (en) | Small molecule inhibitors of kras g12d mutant | |
| ES2877050T3 (es) | Compuestos y composiciones como agonistas del receptor 7 de tipo toll | |
| ES2902390T3 (es) | Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma | |
| JP5432376B2 (ja) | 縮合イミダゾール類および例えばマラリアのような寄生虫症の処置のためのそれらを含む組成物 | |
| JP6769000B2 (ja) | ４’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 | |
| JP2018523679A (ja) | Ｐａｒｐ阻害剤としてのヘテロアリール誘導体 | |
| EP2802587A2 (de) | Substituierte, annellierte imidazole und pyrazole und ihre verwendung | |
| AU2008271114A1 (en) | Novel HIV reverse transcriptase inhibitors | |
| KR20190056425A (ko) | Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체 | |
| TW201213332A (en) | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | |
| JP2015514056A5 (ru) | ||
| JP2010525057A (ja) | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 | |
| US20200039994A1 (en) | Heteroaryl amide compounds as sting activators | |
| WO2021188417A1 (en) | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | |
| US20110223131A1 (en) | Antiviral compounds | |
| HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk | |
| SA520412290B1 (ar) | مركبات جديدة مثبطة للهدف الميكانيكي للراباميسين | |
| JP2013518036A5 (ru) | ||
| RU2012135698A (ru) | Способ и композиция | |
| JP7601800B2 (ja) | アロステリックｅｇｆｒ阻害剤及びその使用方法 | |
| AU2005302519A1 (en) | Compounds and methods of use thereof | |
| WO2010011959A1 (en) | Antiviral compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130109 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20130219 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20150120 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20151120 |
|
| RZ4A | Other changes in the information about an invention | ||
| PD4A | Correction of name of patent owner |